Back to top
more

ADMA Biologics (ADMA)

(Real Time Quote from BATS)

$16.72 USD

16.72
4,215,345

-1.82 (-9.82%)

Updated Aug 7, 2025 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $10.71, indicating a +0.85% shift from the previous trading day.

Zacks Equity Research

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Zacks.com featured highlights ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education

by Zacks Equity Research

ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap May's Rally

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, NTIC, AGS, MBIN, STRA.

Zacks Equity Research

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.

Zacks Equity Research

Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 60% and 6.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Adma Biologics (ADMA) reachead $6.74 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.

Zacks Equity Research

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?

by Zacks Equity Research

On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Santanu Roy headshot

Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus

by Santanu Roy

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.

Zacks Equity Research

Adma Biologics (ADMA) Stock Moves -0.31%: What You Should Know

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $6.44, indicating a -0.31% shift from the previous trading day.

Zacks Equity Research

Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

by Zacks Equity Research

Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.

Zacks Equity Research

BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.

Zacks Equity Research

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.

Zacks Equity Research

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

by Zacks Equity Research

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.

Zacks Equity Research

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

by Zacks Equity Research

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

Kinjel Shah headshot

Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

by Kinjel Shah

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Zacks Equity Research

Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why

by Zacks Equity Research

Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

by Zacks Equity Research

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.

Zacks Equity Research

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

by Zacks Equity Research

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Zacks Equity Research

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

by Zacks Equity Research

Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.

Zacks Equity Research

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

by Zacks Equity Research

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.

Zacks Equity Research

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

by Zacks Equity Research

Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.

Zacks Equity Research

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $6.27, indicating a +1.13% shift from the previous trading day.